Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Empagliflozin Effect on Glucose Toxicity in Type 2 Diabetes Patients - a Randomized, Open-label, Controlled, Parallel Group, Exploratory Study

NCT03437330 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT03437330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03437330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Empagliflozin Effect on Glucose Toxicity in Type 2 Diabetes Patients - a Randomized, Open-label, Controlled, Parallel Group, Exploratory Study
Lead sponsor
University Hospital Tuebingen
Phase
Phase 4
Overall status
Withdrawn
Start date
October 27, 2021
Completion date
May 3, 2023
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

type2 diabetes mellitus